Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

GNC outperforming, issuing shares; Vitacost emerges from strategic review; Fleminger’s green tea QHC remanded back to FDA; supplement firm Modern Products unaware of GMPs; more news In Brief.

You may also be interested in...



Nutrition Market Shifting From Supplements To Whole Foods – Experts

Scientists, market researchers and attorneys see a growing consumer preference for whole plant-based foods, a movement that could cost supplements and functional foods. Communicating nutritional benefits to appease both consumers and regulators will be challenging.

Nutrition Market Shifting From Supplements To Whole Foods – Experts

Scientists, market researchers and attorneys see a growing consumer preference for whole plant-based foods, a movement that could cost supplements and functional foods. Communicating nutritional benefits to appease both consumers and regulators will be challenging.

ChromaDex Looks To Pharma Model For Commercializing Supplement Research

Nutritional ingredient developer ChromaDex is employing a pharma-style business model to expand its R&D into finished dietary supplements – with a long-term eye on pharmaceutical products. The firm’s recent hire of CEO Jeffrey Himmel was a significant step into the consumer products arena.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS105633

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel